Proteomics

Dataset Information

0

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition


ABSTRACT: Performing a targeted drug-screen in isogenic human cell lines, we idenTfied a number of small molecules that specifically targeted CREBBP-mutated B-ALL, with the most potent the BCL2-inhibitor Venetoclax. Of note, this acted through a non-canonical mechanism resulTng in ferroptoTc rather than apoptoTc cell death. CREBBP-mutated cell lines showed differences in cell- cycle, metabolism, lipid composiTon and response to oxidaTve stress, predisposing them to ferroptosis, which were further dysregulated upon acquisiTon of Venetoclax resistance. Lastly, small- molecule inhibiTon of CREBBP pharmacocopies CREBBP-mutaTon, sensiTzing B-ALL cells, regardless of genotype, to Venetoclax-induced ferroptosis in-vitro and in-vivo, providing a potential novel drug combination for broader clinical translation in B-ALL.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Cell Culture

DISEASE(S): B-cell Acute Lymphoblastic Leukemia

SUBMITTER: Dhoyazan Azazi  

LAB HEAD: Brian J.P. Huntly

PROVIDER: PXD061362 | Pride | 2025-05-01

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Lumos_06022023_PR1627_JOK_FR.msf Msf
Lumos_06022023_PR1627_JOK_FR01.raw Raw
Lumos_06022023_PR1627_JOK_FR02.raw Raw
Lumos_06022023_PR1627_JOK_FR03.raw Raw
Lumos_06022023_PR1627_JOK_FR04.raw Raw
Items per page:
1 - 5 of 23

Similar Datasets

2025-03-26 | GSE289012 | GEO
2025-03-26 | GSE289011 | GEO
2025-04-01 | MSV000097461 | MassIVE
2025-03-26 | GSE248265 | GEO
2018-02-07 | PXD008805 | Pride
2025-05-27 | PXD053249 | Pride
2022-03-23 | PXD012098 | Pride
2019-11-15 | GSE131444 | GEO
2025-03-09 | E-MTAB-13917 | biostudies-arrayexpress
2021-02-08 | GSE162069 | GEO